Pentasomy X syndrome

Pentasomy X syndrome, also known as 49,XXXXX syndrome or penta X syndrome, is an extremely rare sex chromosome aneuploidy that occurs exclusively in females, resulting from the presence of five X chromosomes instead of the normal two. This condition arises from nondisjunction errors during meiosis and is not inherited in a traditional Mendelian pattern. It was first described in 1963 and remains one of the rarest chromosomal abnormalities reported in the medical literature. Pentasomy X affects multiple body systems. Key clinical features include intellectual disability, which is typically moderate to severe, short stature, craniofacial abnormalities (such as microcephaly, upslanting palpebral fissures, flat nasal bridge, and micrognathia), skeletal anomalies (including radioulnar synostosis, clinodactyly, and joint laxity), and congenital heart defects (particularly patent ductus arteriosus and ventricular septal defects). Affected individuals may also present with renal malformations and immunological abnormalities. Limb anomalies, including camptodactyly and talipes equinovarus (clubfoot), have been reported. Hypotonia in infancy is common, and speech and motor development are significantly delayed. There is no cure or specific targeted therapy for pentasomy X syndrome. Management is supportive and multidisciplinary, involving early intervention programs, speech therapy, physical therapy, occupational therapy, and special education services. Cardiac defects and other structural anomalies may require surgical correction. Regular monitoring by cardiology, orthopedics, nephrology, and developmental specialists is recommended. Genetic counseling is offered to families, although recurrence risk is generally considered to be low.

Common questions about Pentasomy X syndrome